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Abstract
Background: Integrating rare variation from trio family and case–control studies has successfully implicated specific
genes contributing to risk of neurodevelopmental disorders (NDDs) including autism spectrum disorders (ASD),
intellectual disability (ID), developmental disorders (DDs), and epilepsy (EPI). For schizophrenia (SCZ), however, while
sets of genes have been implicated through the study of rare variation, only two risk genes have been identified.
Methods: We used hierarchical Bayesian modeling of rare-variant genetic architecture to estimate mean effect sizes
and risk-gene proportions, analyzing the largest available collection of whole exome sequence data for SCZ (1,077
trios, 6,699 cases, and 13,028 controls), and data for four NDDs (ASD, ID, DD, and EPI; total 10,792 trios, and 4,058 cases
and controls).
Results: For SCZ, we estimate there are 1,551 risk genes. There are more risk genes and they have weaker effects than
for NDDs. We provide power analyses to predict the number of risk-gene discoveries as more data become available.
We confirm and augment prior risk gene and gene set enrichment results for SCZ and NDDs. In particular, we
detected 98 new DD risk genes at FDR < 0.05. Correlations of risk-gene posterior probabilities are high across four
NDDs (ρ > 0.55), but low between SCZ and the NDDs (ρ < 0.3). An in-depth analysis of 288 NDD genes shows there
is highly significant protein–protein interaction (PPI) network connectivity, and functionally distinct PPI subnetworks
based on pathway enrichment, single-cell RNA-seq cell types, and multi-region developmental brain RNA-seq.
Conclusions: We have extended a pipeline used in ASD studies and applied it to infer rare genetic parameters for
SCZ and four NDDs (https://github.com/hoangtn/extTADA). We find many new DD risk genes, supported by gene set
enrichment and PPI network connectivity analyses. We find greater similarity among NDDs than between NDDs and
SCZ. NDD gene subnetworks are implicated in postnatally expressed presynaptic and postsynaptic genes, and for
transcriptional and post-transcriptional gene regulation in prenatal neural progenitor and stem cells.
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Background
Integrating rare variation from family and case–control
(CC) studies has successfully implicated specific genes
contributing to risk of neurodevelopmental disorders
(NDDs) including autism spectrum disorders (ASD),
intellectual disability (ID), developmental disorders
(DDs), and epilepsy (EPI). These early-onset disorders
typically manifest as infant or childhood developmental
delay or regression, and can be co-morbid even within
individuals [1] at the symptom and syndrome levels.
ASD typically includes deficits in social function and
often includes cognitive deficits. ID is defined by severe
cognitive deficits. DD is characterized by physical or
neurological developmental delays frequently including
ID while EPI is defined by recurrent seizures and often
occurs in probands of the other NDDs [2–4]. Cognitive
dysfunction is a common thread among these disorders
and many of the risk genes identified for them point to
brain neuronal development as well as synaptic function.
For schizophrenia (SCZ), however, while sets of genes
have been implicated through studying rare variation
(including NDD risk genes) [5–7], only two risk genes
containing rare exonic variants with a strong effect have
been identified [6, 8, 9]. SCZ is an etiologically complex
psychiatric disorder characterized by hallucinations, delu-
sions, and cognitive symptoms. Heritability is estimated
to be 60–80% [10, 11] and the genetic architecture of
SCZ is highly polygenic with contributions from common
variation and rare inherited and de novo (DN) struc-
tural and exonic variants [5–8, 12–15]. With the advent
of affordable high-quality next-generation sequencing, the
genetics of SCZ and other diseases are increasingly being
better characterized, especially for rare variants. Rare
variants in CC and trio samples have been leveraged to
identify SCZ genes and gene sets. However, the SCZ rare-
variant genetic architecture remains poorly understood.
Such analyses could help gain further insights into this
disease, for example, by using the estimated number of
risk genes to calibrate false discovery rates (FDRs) for
gene discovery or by using the distribution of effect sizes
to improve power estimates and rare-variant association
study design. A better understanding of our certainty for
sets of risk genes for SCZ will provide a better picture of
biological pathways relevant for the disease.
We developed an improved hierarchical Bayesian mod-
eling framework [16], Extended Transmission and de
novo Association (extTADA), to analyze whole exome
sequence data in SCZ and four NDDs (ASD, ID, DD,
and EPI), which have substantial clinical and etiological
overlap. All are brain diseases with prominent impacts
on cognitive function. Multiple recent studies support-
ing genetic overlap among these disorders have included
common variant genetic correlations [17, 18], shared
molecular pathways [19, 20], and shared genes with DN
mutations [6, 21]. Using the largest sample assembled
to date for a unified analysis of these disorders, we
find greater overlap among the NDDs than with SCZ,
despite the emphasis on overlap in the SCZ rare-variant
literature [6, 7, 19]. We used the statistical support of
extTADA to compile a comprehensive list of 288 NDD
genes. Network analyses of these genes are beginning to
pinpoint and intersect functional processes implicated in
disease, brain cell types, and developmental time points
of expression.
Methods
Data
Additional file 1: Figure S1 shows the workflow for all data
used in this study.
Variant data for SCZ, ID, DD, EPI, and ASD
High-quality variants were obtained from published anal-
yses as shown in Additional file 1: Table S1. These
included DN data for SCZ and four NDDs, and CC data
for SCZ and ASD. Quality control and validation for
these data were carried out within the original studies
(Additional file 1: Table S1). To maintain consistency
across data sets, we re-annotated all of the variants in our
analyses. For SCZ CC data, we performed exome-wide
association analyses with andwithout covariates to test for
stratification, and used clustering of CC samples to iden-
tify non-heterogeneous samples for extTADA analysis
(see Additional file 1: Methods).
Variants were annotated using Plink/Seq (using Ref-
Seq gene transcripts and the UCSC Genome Browser
[22]) as described in Fromer et al. [6]. SnpSift version
4.2 [23] was used to annotate these variants further
using dbnsfp31a [24]. Variants were annotated as fol-
lows: loss of function (LoF) (nonsense, essential splice,
and frameshift variants); missense damaging (MiD)
(defined as missense by Plink/Seq and damaging by
each of seven methods [7]: SIFT, Polyphen2_HDIV,
Polyphen2_HVAR, LRT, PROVEAN, MutationTaster, and
MutationAssessor); missense; synonymous mutations
within DNase I hypersensitive sites (DHSs) [25], using
wgEncodeOpenChromDnaseCerebrumfrontalocPk.narrow
Peak.gz from ENCODE [26, 27] (downloaded 20 April
2016); and synonymous. Based on previous results with
SCZ exomes [5, 7], only CC singleton variants were used
in this study (i.e., they were observed once). The data
from the Exome Aggregation Consortium (ExAC) [28]
were used to annotate variants as inside ExAC (InExAC
or not private) or not inside ExAC (NoExAC or private),
using ExAC.r0.3.nonpsych.sites.vcf.gz (downloaded from
[29] 20 April 2016) and BEDTools.
The variant categories used in extTADA were LoF,
MiD, and silent within frontal cortex-derived DHS peaks
(silentFCPk).
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Mutation rates
We used the methodology based on trinucleotide context
[30, 31] and incorporating depth of coverage [6] to obtain
mutation rates for each variant annotation category. We
assigned 1/10 of the minimum non-zero mutation rate to
genes with calculated mutation rates equal to zero.
Gene sets
Multiple resources were used to obtain gene sets for our
study. First, we used known and candidate gene sets with
prior evidence of involvement in SCZ andASD. Second, to
identify possible novel significant gene sets, we collected
genes sets from available data bases (see below).
Known/candidate gene sets These gene sets and their
abbreviations are presented in Additional file 1: Table S2.
They included: gene sets enriched for ultra rare variants
in SCZ which were described in detailed in Supplemen-
tary Table 5 of [7] consisting of missense constrained
genes (constrained) from [30], loss-of-function intolerant
genes (pLI90) from [28], RBFOX2 and RBFOX1/3 target
genes (rbfox2, rbfox13) from [32], Fragile X mental retar-
dation protein target genes (fmrp) from [33],CELF4 target
genes (celf4) from [34], synaptic genes (synaptome) from
[35], microRNA-137 (mir137) from [36], PSD-95 com-
plex genes (psd95) from [37], ARC and NMDA receptor
complexes (arc, nmdar) genes from [38], and de novo
copy number variants in SCZ, ASD and bipolar dis-
order; allelic-biased expression genes in neurons from
Table S3 of [39]; promoter targets of CHD8 from [40];
known ID gene set from the Sup Table 4 and the 10
novel genes reported by [41]; gene sets from MiD and
LoF de novo mutations of ASD, EPI, DD, ID; the essen-
tial gene set from the supplementary data set 2 of [42];
lists of human accelerated regions (HARs) and primate
accelerated regions (PARs) [43] (downloaded May 11,
2016 from [44]; genes within 100kb [45]) (geneInHARs,
geneInPARs); known epilepsy genes from Supplementary
Table 3 of [46]; common-variant genes from Extended
Table 9 of [15]; 24 co-expression modules from Supple-
mentary Table 2 of [47]; and 134 gene sets from mouse
mutants with central nervous system (CNS) phenotypes
were obtained from [15, 48].
In the gene-set tests for a given disease, we removed the
list of known genes and the list of DN mutation genes for
that disease. As a result, we tested 185 candidate gene sets
for ASD, DD, and SCZ, and 184 candidate gene sets for
EPI and ID.
Other gene sets We also used multiple data sets to iden-
tify novel gene sets overlapping with the current gene
sets. We assembled gene sets from the Gene Ontology
data base [49], KEGG, and REACTOME, and the C3
motif gene sets collected for the Molecular Signatures
Database (MSigDB) [50] plus the gene sets from The
Mouse Genome Database [51]. To increase the power
of this process, we used only gene sets with between
100 to 4,995 genes. In total, there were 2,084 gene sets.
These gene sets and the above gene sets were used in
this approach.
Transcriptomic data
Spatiotemporal transcriptomic data were obtained from
BRAINSPAN [52]. The data were divided into eight devel-
opmental time points (four prenatal and four postnatal)
[53]. Single-cell RNA-seq data were obtained from [54].
The extTADA pipeline
Recently, He et al. developed the Transmission and de
novo Association (TADA) pipeline, which integrates DN
and inherited (or CC) variants to increase power in the
identification of risk genes for ASD [16, 31]. TADA bor-
rows information across variant categories of DN and CC
samples in gene-level association analysis, which is critical
for sparse rare-variant sequence data, and showed better
power than the traditional approach of combining p values
from multiple data sets using Fisher’s method [16].
TADA assumes that a proportion of all genes (π ) com-
prise risk genes. Therefore, for each gene, TADA compares
two hypotheses: risk gene (H1) or non-risk gene (H0).
The method combines multiple categories of DN and CC
variants; however, TADA is an empirical Bayesian asso-
ciation method with respect to model parameters and
does not provide any uncertainty information (e.g., confi-
dence intervals) [16]. TADA uses a simple CC model with
parameter ranges that can imply protective variants in its
CC model [16, 31]. Here, we extend TADA into a flexible
and convenient model, which can be applied to differ-
ent population samples, including DN and CC data alone
or in combination. The new pipeline, Extended Trans-
mission and de novo Association, extTADA (Additional
file 1: Figure S2 and Table S3), uses a Markov chain Monte
Carlo (MCMC) approach to sample the joint posterior
of all genetic parameters given all variant categories, in
one step. The current pipeline provides Bayesian credible
intervals (CIs) for estimated parameters.
Additional details are in Additional file 1: Methods and
https://github.com/hoangtn/extTADA. Briefly, for a given
gene, all variants of a given category (e.g., either DN or
singleton CC LoF) were collapsed and considered as a
single count. Let γ be the relative risk (RR) of the vari-
ants, which is assumed to follow a distribution across risk
genes: γ ∼ Gamma(γ¯ × β ,β). γ¯ and β are hyperparam-
eters of γ as presented in Additional file 1: Table S3. The
data likelihood was considered a mixture of non-risk and
risk-gene hypotheses, H0: γ = 1 and H1: γ = 1:
P(x|H1,H0) = πP(x|H1) + (1 − π)P(x|H0), (1)
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where H0 and H1 represent γ and all other parame-
ters under the model, and the mixture proportion π is
interpreted as the proportion of risk genes genome-wide.
The data x are DN and CC variant counts (xdn, xca, xcn
for de novo, case and control data respectively). We
assumed that these data are from independent vari-
ant categories and independent population samples. The
extTADA likelihood is the product of data probabili-
ties over any number of population samples and variant
categories. The hyperparameters (γ¯ and β) for different
categories and π (Additional file 1: Table S3) were jointly
estimated based on the mixture model,
P(x|φ1,φ0) =
Gene Number∏
i=1
[πP1i + (1 − π)P0i] , (2)
where φ1 and φ0 are sets of parameters of all population
samples and categories. P1i and P0i at the ith gene were
calculated across population samples and categories as
follows:
Pji = Pji(xi|φj)
= [Pji(dn)(xi(dn)|φj(dn))
] [
Pji(cc)(xi(ca), xi(cn)|φj(cc))
]
=
⎛
⎝
Ndnpop∏
h=1
Cdn∏
k=1
Pji(dn)hk (xi(dn)hk |φj(dn)hk )
⎞
⎠
×
⎛
⎝
Nccpop∏
a=1
Ccc∏
b=1
Pji(cc)ab (xi(ca)ab , xi(cn)ab |φj(cc)ab )
⎞
⎠ , j = 0, 1.
Ndnpop and Nccpop are the numbers of DN and CC
population samples, and Cdn and Ccc are the numbers of
annotation categories in the DN and CC data.
To simplify the estimation process in Eq. 2, we approxi-
mated the original TADAmodel for CC data P(xca, xcn|Hj)
using a new model in which case counts were con-
ditioned on total counts: P(xca|xca + xcn,Hj), and we
constrained the effect size distribution dispersion param-
eter (β) to prevent an implied proportion of protec-
tive variants (Additional file 1: Figures S2 and S3 and
Additional file 1: Methods).
extTADA uses a MCMC approach for Bayesian analy-
sis. We extracted posterior density samples from at least
two MCMC chains for simulated data and at least three
chains for real data. Posterior modes were reported as
parameter estimates for all analyses, with 95% CIs.
Then, gene-level Bayes factors (BFgene) can be calcu-
lated for each variant category to compare hypotheses H1
and H0 (BF = P(x|H1)/P(x|H0)). Data could be from het-
erogeneous population samples; therefore, we extended
TADA’s BFgene as the product of BFs of all variant cate-
gories including population samples as in
BFgene =
⎡
⎣
Ndnpop∏
h=1
Cdn∏
k=1
BFdnhk
⎤
⎦
⎡
⎣
Nccpop∏
a=1
Ccc∏
b=1
BFccab
⎤
⎦ .
(3)
We changed the order of integrals in the BF calcula-
tions to avoid numerical integration over P(q) because
the true range of this parameter is not known (Additional
file 1). We inferred significant genes by converting BFs to
FDRs using the approach of [55] as described in [31]. The
posterior probability (PP) for each gene was calculated as
PP = π × BF/(1 − π + π × BF) [56].
Testing the pipeline on simulated data
To test extTADA, we used the simulation method
described in the TADA paper [16]. To check the approx-
imate model of CC data, we simulated one CC variant
class and two CC variant classes. To check the integrated
model for both CC and DN, we simulated one CC and
one DN variant class. The original CC model in TADA
[16] was used to simulate CC data and then CC param-
eters were estimated using the approximate model. To
make the data more similar to real data, the frequency
of SCZ CC LoF variant counts was used to calculate the
prior distribution of q ∼ Gamma(ρ, ν) as described in
Additional file 1: Table S3.
Different sizes of samples were used. For CC data, to see
the performance of the approximate model, we used four
sample sizes: 1,092 cases plus 1,193 controls, 3,157 cases
plus 4,672 controls, 10,000 cases plus 10,000 controls, and
20,000 cases plus 20,000 controls. The first two sample
sizes were exactly the same as the two sample sizes from
the Sweden data in current study. The last two sample
sizes were used to see whether the model would perform
better if sample sizes were increased. For DN and CC data,
we used exactly the sample sizes of the largest groups
in our current data sets: 1,077 families, 3,157 cases, and
4,672 controls.
To assess the performance of model parameter esti-
mation, we calculated Spearman correlation coefficients
[57] between estimated and simulated parameter values.
For each combination of simulated parameters, we reran
the model 100 times and used the medians of estimated
values. We also used different priors for the hyperparam-
eters (e.g., ¯¯γ and β¯ in Additional file 1: Table S3) in the
simulation process and chose the most reliable priors cor-
responding with ranges of γ¯ . Because β¯ mainly controlled
the dispersion of hyperparameters, ¯¯γ was set equal to 1,
and only β¯ was tested.
To assess the performance of extTADA risk-gene iden-
tification, we compared expected and observed FDRs
(oFDRs). We defined oFDR as the proportion of FDR
significant genes that were true risk genes (determined
for data simulation). We simulated DN and CC data
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for a range of sample sizes, using parameter values ran-
domly sampled from the posterior density of our primary
SCZ analysis.
We also conducted power analyses of larger sample SCZ
studies using parameters sampled from the posterior den-
sity of our primary SCZ analysis. For power analyses, we
assumed sample sizes ranging from 500 to 20,000 trio
families and equal numbers of cases and controls ranging
from 1,000 to 50,000 of each, and calculated the number
of risk genes at FDR ≤ 0.05.
We also tested when there was no signal for both
DN mutations and rare CC variants. We simulated one
DN category and one CC category with π = 0 and
γ¯ = 1. To see the influence of prior information of γ¯
(γ¯ ∼ Gamma(1, β¯)) for these results, we used different
values of β¯ .
Applying extTADA to real data
Estimating genetic parameters For SCZ, we analyzed
DN mutations and CC variants from non-heterogeneous
population samples. Three DNmutation categories (MiD,
LoF, and silentFCPk mutations) and one CC variant cat-
egory (MiD and LoF variants, pooled) were used in
Eq. 2 to obtain genetic parameters for SCZ. Detailed
analyses of SCZ data are described in Additional file 1:
Methods. We performed exome-wide association analy-
ses with and without covariates to test for stratification,
and used clustering to identify non-heterogeneous sam-
ples for extTADA analysis. For ASD, two DN (MiD and
LoF) and one CC (MiD and LoF pooled) variant categories
were analyzed. For the three other disorders, only DN data
(MiD and LoF categories) were analyzed because no rare
CC data were available.
Secondary analyses We compared our results with those
generated using mutation rates adjusted for the ratio
of observed to expected synonymous mutations. We
divided the observed counts by expected counts (= 2 ×
family numbers×total mutation rates), and then used this
ratio to adjust for all variant category mutation rates.
We conducted further analyses of the SCZ data. Each
variant category (LoF, MiD, silentFCPk DN mutations,
and LoF+MiD CC variants) was analyzed individually to
assess its contributions to the primary results. We con-
ducted secondary analyses including CC variants present
in ExAC, and with equal mean RR parameters (γ¯CC and
βCC) across CC population samples.
Running TADA on the current data sets We also ran
TADA for all the current data sets. To compare the results
of extTADA and TADA, TADA was run directly from vari-
ant counts as extTADA. We used the method of moments
implemented in TADA to estimate π and γ¯LoF,DN, and
then the burden of other variant categories was calculated
by dividing case counts by control counts. Gene-level
association tests were then conducted as implemented in
TADA. The results are shown in Additional file 1: Results,
Table S4, and Figure S4.
Gene set enrichment in extTADA results
Based on the extTADA results, we tested the enrichment
of gene sets by using gene PPs as follows. For each gene, we
obtained PP from extTADA. For each gene set tested, we
calculated the mean of PPs (m0). After that, we randomly
chose gene sets matched for mutation rates and recal-
culated mean PP n times (n = 10 million in this study)
(generating the vector m). The empirical p value for the
gene set was calculated as
p = length(m [m > m0]) + 1length(m) + 1 .
To correct for multiple tests, the p values were FDR
adjusted using the method of [58]. To match mutation
rates, for each gene, we chose random genes from the
1,000 genes with the closest mutation rates.
To test the results of the mean-PP-based method above,
we also compared the method with a permutation-based
method. For each condition, we chose the top 500 genes
with the smallest FDR values from the extTADA results.
For each gene set, we calculated the number of overlap-
ping genes between the 500 genes and the gene set (m0).
After that, we randomly chose gene sets having the same
length as the tested gene set, and recorded the intersect-
ing gene number with the top 500 genes. This process was
carried out n times to produce a vectorm (n = 10,000,000).
The matching of genes by mutation rate and the empirical
p value calculation were as described above.
Post hoc analysis of significant genes and gene length
Different FDR thresholds were used to test whether sig-
nificant genes could be affected by gene length. For each
FDR threshold, the mean gene length of significant genes
(m0) was calculated. Next, N gene sets (N = 10,000 in
this study) were randomly generated from genes having
DN mutations, and their mean gene lengths (m) were
calculated. The p value was calculated as
length(m [m > m0]) + 1
length(m) + 1 .
pLI/RVIS data in novel significant gene sets
Residual variation intolerance score (RVIS) information
(RVIS_Unpublished_ExACv2_March2017.txt) was down-
loaded from [59] and information on the probabilities of
LoF intolerance (pLI) was downloaded from [60] on 20
June 2017. To calculate p, μ, σ , and z for a gene set, we
used the same approach as [41] with 10,000 permutations.
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Single-cell enrichment analysis
We obtained gene expressions from 9,970 single cells that
were previously clustered into 24 different cell types [54].
We used the scran R package [61, 62] using the 50% of
the genes with mean expression higher than the median
to compute a normalization factor for each single cell.
The normalization factors were computed after cluster-
ing cells using the scran quickcluster() function to
account for cell type heterogeneity. We then performed
24 differential expression analyses using BPSC [63], test-
ing each cell type against the 23 other cell types using
the normalization factors as covariates. For each differen-
tial expression analysis, the t-statistics were then standard
normalized. Finally, for each cell type, we tested if the
standard normalized t-statistic for genes in the gene sets
was significantly higher than that for genes not in the
gene set.
Network and transcriptome analyses
We used GeNets [64] to test protein interactions from the
gene sets. Connectivity p values were obtained by permut-
ing 75,182 matched random networks, and communities
(subnetworks showing greater connectivity within than
between) were defined by hierarchical agglomeration [65].
Spatiotemporal transcriptome data were clustered using
a hierarchical method inside heatmap.2 of the pack-
age gplots [66]. We used a height of 9 (in the function
cutree) to divide the data from the clustering results
into eight groups. Default options were used for this clus-
tering process. Fisher’s exact test [67] was used to obtain
p values between spatiotemporal transcriptome clusters
and GeNets-based communities.
Results
The extTADA pipeline for rare-variant genetic architecture
inference
We present a pipeline for integrative analysis of trio-based
DN variants and CC rare variants, to infer rare-variant
genetic architecture parameters and to identify disease
risk genes. We extended the hierarchical Bayesian mod-
eling framework of He et al. [16] to develop extTADA
(Additional file 1: Figure S2 and Table S3) for Bayesian
analysis via MCMC.
Evaluating extTADA on simulated data We analyzed
simulated DN and CC data with one variant category
each and CC data with two variant categories, to exam-
ine inference on a single variant class as well as to
assess the conditional probability approximation for CC
data (Additional file 1: Figures S5–S8, Additional file 1:
Results). We tested sample sizes ranging from that of
the available data, 1077 trios and 3157 cases (equal con-
trols), and larger sample sizes of up to 20,000 cases
(see Additional file 1: Results).
We observed little bias in parameter estimation
(Additional file 1: Tables S5 and S6). With very large RR
of the inherited variants, we observed slight under- and
overestimation of the risk-gene proportion (πˆ ) and mean
RR ( ˆ¯γ ), respectively. We note that these conditions appear
outside the range of our SCZ analyses. Some bias can be
expected in Bayesian analysis and does not have a large
effect on risk-gene identification under this model [16].
We assessed this directly by calculating oFDR, i.e., the
proportion of genes meeting a given FDR significance
threshold that are true simulated risk genes). extTADA
risk-gene identification results were calibrated well (Fig. 1)
over wide parameter ranges. For small π (e.g., π = 0.02),
oFDRs were higher than FDRs when DN mean RRs (γ¯ )
were small (∼5). We also observed oFDRs were equal to
zero for some cases with small FDR, when very small
numbers of FDR-significant genes were all true risk genes.
We also ran extTADA on null data, π = 0 and γ¯ = 1,
for both DN and CC data (Additional file 1: Table S7).
Here, MCMC chains tended not to converge, π esti-
mates trended to very small values, and BFs and FDRs
identified almost no FDR-significant genes as expected
(Additional file 1: Table S7).
Data for analyses
Schizophrenia
We applied extTADA to the largest available DN and
CC SCZ whole exome sequence data, for inference
of rare-variant genetic architecture parameters and for
genic association. In total, 6,699 cases, 13,028 controls,
1,077 trio/quad families were analyzed (Additional file 1:
Table S1). Primary analyses included three variant cat-
egories for DN data (LoF, MiD, and silentFCPk) and a
single category of CC singletons [5, 7] not present in the
ExAC data (termed NoExAC) [28]: LoF+MiD. An array
of secondary extTADA analyses were conducted to help
validate and dissect our results.
DN mutations and CC variants were tested to select
classes and samples for the extTADA pipeline. For DN
mutations, we calculated the sample-adjusted ratios of
mutation counts between 1,077 DN cases and 731 DN
controls (Additional file 1: Table S1). Like [25], the highest
ratio was observed for silentFCPk (2.57), followed by MiD
(2.3), LoF (1.83), andmissense and silent (∼1.3) mutations
(Additional file 1: Figure S9). Three classes (LoF, MiD, and
silentFCPk) were used in extTADA analyses.
Since currently extTADA requires integer counts data,
adjustment for ancestry and technical covariates is not
possible. We performed exome-wide association analy-
ses with and without covariates to test for stratification,
and used CC samples to obtain homogeneous popula-
tion samples (see Additional file 1: Methods). First, for
the 4929 cases and 6232 controls from the Sweden pop-
ulation sample, we clustered all cases and controls based
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Fig. 1 Observed false discovery rates (oFDRs) and theoretical FDR with different combinations between γ¯dn and γ¯cc. Each panel is for one π value.
For example, the top left panel shows oFDR and FDR for π = 0.02. FDR false discovery rate, dn de novo, FDR false discovery rate, oFDR observed
FDR, RR relative risk
on principal components analysis and tested each clus-
ter for CC differences with and without adjustment for
covariates. We carried two clusters forward for analy-
sis (groups 1 and 3 in Additional file 1: Figure S10),
one with 3,157 cases and 4,672 controls, and the other
with 1,091 cases and 1,193 controls. We used only the
larger UK population sample from the UK10K project
data [8], as it showed comparable CC differences to the
homogenous Sweden samples. As in [7], NoExAC single-
ton CC variants showed significant CC differences and
InExAC variants did not (Additional file 1: Figure S10);
therefore, we used only NoExAC CC singletons in the
primary extTADA analyses. However, we also used all sin-
gletons in a secondary analysis for comparison. LoF and
MiD variants showed similar enrichment in our CC data
(Additional file 1: Figure S10); therefore, we pooled them
to maximize the CC information.
Neurodevelopmental disorders
The sample sizes for these diseases are shown in
Additional file 1: Table S1 and Figure S1. The numbers
of trios ranged from 356 for EPI, 1,112 for ID, and 4,293
for DD to 5,122 for ASD. As previously reported (see
references in Additional file 1: Table S1), these data have
strong signals for DN mutations contributing to disease
(Additional file 1: Table S8). Only ASD data included CC
samples (404 cases and 3,654 controls) from the Swedish
PAGES study of the Autism Sequencing Consortium [31]
(see Additional file 1: Methods for details).
Rare-variant genetic architectures inferred by extTADA
Schizophrenia
extTADA generated joint posterior density samples of all
genetic parameters for SCZ (Table 1, Fig. 2, and Additional
file 1: Figure S11). All MCMC chains showed convergence
(Additional file 1: Figure S12). The estimated proportion
of risk genes (πˆ ) was 8.01% of the 19,358 genes analyzed
(1,551 genes), with 95% CI (4.59%, 12.9%; 890 to 2,500
genes). DN LoF variants had the highest estimated mean
RR ( ˆ¯γ ), 12.25 (95% CI: 4.78-22.22). Estimated mean RRs
( ˆ¯γ ) were 1.22 (95% CI: 1-2.16) for silentFCPk and 1.44
(95% CI: 1-3.16) for MiD. For CC MiD+LoF variants, the
two Sweden samples had nearly equal mean RR estimates
( ˆ¯γ ), 2.09 (95% CI: 1.04-3.54) and 2.44 (95% CI: 1.04-5.73),
which were larger than that of the UK sample, 1.04 (95%
CI: 1-1.19).
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Table 1 Estimated parameters of proportions of risk genes (pi) and mean relative risk (meanRR) for DN and CC SCZ data and four other
NDDs: ID, EPI, ASD and DD
Parameter Estimated Lower credible Upper credible
mode interval boundary interval boundary
SCZ_pi (%) 8.01 4.59 12.9
SCZ_meanRR_silentFCPk_denovo 1.22 1.00 2.16
SCZ_meanRR_MiD_denovo 1.44 1.00 3.16
SCZ_meanRR_LoF_denovo 12.25 4.79 22.22
SCZ_meanRR_MiD+LoF_CCpop1 2.09 1.04 3.54
SCZ_meanRR_MiD+LoF_CCpop2 2.44 1.05 5.73
SCZ_meanRR_MiD+LoF_CCpop3 1.04 1 1.19
ASD_pi (%) 4.44 3.15 5.94
ASD_meanRR_MiDdenovo 3.71 2.06 8.71
ASD_meanRR_LoFdenovo 24.56 14.27 37.44
ASD_meanRR_LoFcc 4.04 2.08 8.24
ID_pi (%) 2.53 1.89 3.43
ID_meanRR_MiDdenovo 29.82 18.86 46.1
ID_meanRR_LoFdenovo 105.45 73.27 143.29
DD_pi (%) 2.84 2.29 3.45
DD_meanRR_MiDdenovo 23.42 13.97 33.97
DD_meanRR_LoFdenovo 88.32 67.54 115.09
EPI_pi (%) 1.14 0.52 2.1
EPI_meanRR_MiDdenovo 72.2 35.39 128.46
EPI_meanRR_LoFdenovo 89.71 45.31 169.43
These results were obtained by sampling three MCMC chains (20,000 times for each chain). These results are for three categories: loss of function (LoF) variants/mutations,
missense damaging (MiD) variants/mutations, and silent within frontal cortex-derived DHS peaks (silentFCPk) variants.
ASD autism spectrum disorders, CC case–control, DD developmental disorder, DN de novo, EPI epilepsy, ID intellectual disability, LoF loss of function,MCMC Markov chain
Monte Carlo,MiDmissense damaging, NDD neurodevelopmental disorder, SCZ schizophrenia, silentFCPk silent within frontal cortex-derived DHS peaks
To test the performance of the pipeline on individual
categories and to assess their contributions to the overall
results, we ran extTADA separately on each of four single
variant classes: silentFCPk, MiD, and LoF DN mutations,
and MiD+LoF CC variants (Additional file 1: Table S9).
All parameter estimates were consistent with the primary
analysis, with broader CIs. The much larger γ¯ CIs than in
integrative analyses demonstrated extTADA’s borrowing
of information across data types (also observed in simula-
tion, Additional file 1: Figure S6). To understand conver-
gence in these analyses better, we increased MCMC chain
numbers to five for each analysis. LoF DN and MiD+LoF
CC chains showed strong convergence, followed by MiD
DN. As expected, silentFCPk results (with only 53 muta-
tion counts) showed a lack of strong convergence.
We also assessed the sensitivity of genetic parame-
ter inference in several secondary analyses. We tested
extTADA for DN mutations not present in the ExAC
database, mutation rates adjusted for the ratio of
observed to expected synonymous DN mutations, and
an alternative model specification of variant annotation
categories. We adjusted mutation rates by a factor of
0.81, the ratio of observed synonymous mutations to that
expected based on mutation rates (See ‘Methods’). DN
mean RR estimates slightly increased as expected, and the
estimated proportion of risk genes increased slightly to
9.37% (95% CI: 5.47-15.12%), while the CC parameters
were very similar (Additional file 1: Table S10). Above,
we assumed that different CC population samples may
have different mean RRs, which could be due to clin-
ical ascertainment, stratification, or population-specific
genetic architectures. Analysis using a single mean RR
parameter for all three CC samples yielded similar π and
DNMmean RRs and an intermediate CCMiD+LoF mean
RR with a relatively narrower CI, γ¯CC = 1.93 (95% CI
1.08–3.21) (Additional file 1: Table S11 and Figure S13).
Considering all CC singleton variants (not just those
absent from ExAC) also generated similar genetic
parameter estimates, with slightly lower CC mean RRs
(Additional file 1: Table S12).
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Fig. 2 The densities of the proportion of risk genes (x-axis) and mean
relative risk (y-axis) for SCZ data. These were obtained after 20,000
iterations of three MCMC chains. The first two case–control
populations are derived from the Sweden data set while the third
case–control population is the UK population. The scales on the y-axes
are adjusted because mean relative risk varies between categories.
LoF loss of function, MCMC Markov chain Monte Carlo, MiD missense
damaging, Pop population, SCZ schizophrenia, silentFCPk, silent
within frontal cortex-derived DNase I hypersensitive site peaks
ASD, ID, DD, and EPI
extTADA genetic parameter estimates are presented in
Table 1, Fig. 3, and Additional file 1: Figure S11. MCMC
analyses showed good convergence, except for the EPI
data with small sample size (356 trios compared with over
1,000 trios for other diseases). Estimated risk-gene pro-
portions (πˆ ) for the NDDs were lower than that of SCZ.
For ASD, the estimated π was 4.44%, (3.15%, 5.94%) or
859 (610–1150) risk genes, consistent with the result of
550–1,000 genes estimated in the original TADA model
[16] using only DN LoF data. For DD and ID, the π
estimates were similar, 2.84% or 550 risk genes (2.29%,
3.45%; 443–668 genes) and 2.53% or 490 risk genes (1.89%,
3.43%; 366–664 genes), respectively, which was smaller
than that for ASD. The estimated π value for EPI, 1.14%
or 221 risk genes (0.52%, 2.1%; 101–407 genes), was the
lowest but with a broad CI. The estimated mean RRs of
DN mutations in all four NDDs were much higher than
those of SCZ, indicating a stronger contribution of DN
mutations in these four NDDs. For ASD, the estimated
mean RRs for DN mutations were consistent with previ-
ous results and much lower than for the other diseases. ID
and DD had the highest estimated DN LoF mean RRs ( ˆ¯γ ),
105.45 (73.27, 143.29) and 88.32 (67.54, 115.09), respec-
tively. Even though the EPI estimated DN LoF mean RR
( ˆ¯γ ), 89.71 (45.31, 169.43), was similar to those of ID and
DD, the estimate for the EPI DN MiD mean RR, 72.2
(35.39, 128.46), was somewhat higher than those of the
other diseases. The previously estimated EPI mean RR of
81 [68] is consistent with the current results, and it will
be of interest to see if this result remains consistent in
additional data in the future.
Identification of risk genes using extTADA
Schizophrenia
Additional file 2: Table S13 includes supporting data as
well as association results for SCZ. Four genes achieved
PP > 0.8 and FDR < 0.1 (SETD1A, TAF13, PRRC2A,
and RB1CC1). Two genes, SETD1A (FDR = 0.0033)
and TAF13 (FDR = 0.026), were individually signifi-
cant at FDR < 0.05. SETD1A has been confirmed as
statistically significant in previous studies [8, 25], while
TAF13 was reported as a potential risk gene only in
the study of [6]. However, FDR was high (0.74) for the
gene RBM12, which was reported as a risk gene for psy-
chosis by [9]. If we increase the FDR threshold to 0.3,
as in a recent ASD study, using TADA [31] we identify
24 candidate SCZ risk genes (SETD1A, TAF13, RB1CC1,
PRRC2A, VPS13C, MKI67, RARG, ITSN1, KIAA1109,
DARC, URB2, HSPA8, KLHL17, ST3GAL6, SHANK1,
EPHA5, LPHN2, NIPBL, KDM5B, TNRC18, ARFGEF1,
MIF, HIST1H1E, and BLNK ). Of these, EPHA5, KDM5B,
andARFGEF1 did not have any DNmutations (Additional
file 2: Table S13). We note that still more genes show sub-
stantial support for the alternative hypothesis over the null
model [69] (58 genes with PP > 0.5, corresponding to BF
> 11.49, FDR < 0.391; Additional file 2: Table S13). We
note that the secondary analyses slightly impacted support
for individual genes (Additional file 1: Tables S11 and S12,
Additional file 2: Table S14).
Neurodevelopmental disorders
The results for the extTADA risk gene of the four disor-
ders ID, DD, ASD, and EPI are presented in Additional
file 2: Tables S15–S18. With FDR < 0.05, there were 56,
160, 49, and 9 significant genes for ID, DD, ASD, and EPI.
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Fig. 3 The densities of the proportion of risk genes (x-axis) and mean relative risk (y-axis) for ASD, EPI, ID, and DD data. These were obtained after
20,000 iterations of three MCMC chains. For ASD, there are two de novo classes and one case–control class. For other disorders, only two de novo
classes are publicly available for our current study. The scales on the y-axes are adjusted because mean relative risk varies between categories and
disorders. ASD autism spectrum disorders, DD developmental disorder, EPI epilepsy, ID intellectual disability, LoF loss of function, MCMC Markov
chain Monte Carlo, MiD missense damaging
For FDR < 0.1, there were 69, 196, 64, and 10 significant
genes.
The genetic parameters inferred after adjusting muta-
tion rates for observed silent DN rates are presented
in Additional file 1: Table S10. For ASD, ID, and
EPI, the proportions of risk genes were higher than
in the primary analyses because the adjustment ratios
were less than 1. As a result, the number of signif-
icant genes also increased with different FDR thresh-
olds. For DD, the adjustment ratio was >1 (1.16) and
the number of significant genes decreased (134 genes
with FDR < 0.05). Altogether, 72/134 genes were not
among the 93 DD genes reported in a previous study
[70], 33 of which were in the list of curated DD
genes [71].
We also tested the correlation between gene length and
top genes with three different FDR thresholds: 0.05, 0.1,
and 0.3. No significant results were observed for these cor-
relations (adjusted p ≥ 0.25). Only for ASD genes with
FDR < 0.05 was a slight gene-size effect observed (unad-
justed p = 0.05, adjusted p = 0.25, Additional file 1:
Table S19).
Novel significant genes in ID and DD The results
for the other DN mutation methods using these same
data have been recently reported [41, 70]; nevertheless,
extTADA identified novel genes with strong statistical
support from these recent data.
For ID, we found 56 and 69 genes with FDR ≤ 0.05
and 0.1, respectively. We compared these results with the
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risk-gene list of [41], which included previously reported
and novel ID genes. Altogether, 14 of 56 genes with
FDR ≤ 0.05 (AGO1, AGO2, ATP8A1, CEP85L, CLTC,
FBXO11, KDM2B, LRRC3C, MAST1, MFN1, POU3F3,
RPL26, TNPO2, and USP7) were not on the list. Of the
14 genes, six (AGO2, CEP85L, CLTC, FBXO11, MFN1,
and TNPO2) were strongly significant (FDR< 0.01); these
were genes hit by two or three MiD or LoF DNs that
were not identified by the analyses of [41]. pLI and RVIS
information were obtained for 12 of these 14 genes, and
tested using the method of [41]. The median of pLIs
was 1 (observed 1; simulated data: μ = 0.11, σ = 0.17,
z = 5.08, empirical p < 9.99 × 10−5). In addition, nine
genes (AGO1, AGO2, ATP8A1, CLTC, FBXO11, KDM2B,
MAST1, TNPO2, and USP7) had pLI = 1 and one gene
(RPL26) had pLI = 0.916. The median of the RVISs was
−1.49 (observed −1.49; simulated data: μ = −0.014,
σ = 0.21, z = −7.03, empirical p < 9.99 × 10−5). Two
genes (CLTC and FBX011) were in the latest list of curated
DD genes released on 18 May 2017 [71]. After removing
these two genes, pLI was still highly significant (observed
median 1; simulated data: μ = 0.3, standard deviation =
0.39, z = 1.7, empirical pwas<9.99×10−5), and the RVIS
information was notmuch different (observed−1.48; sim-
ulated data: μ = −0.01, σ = 0.23, z = −6.26, empirical
p < 9.99 × 10−5).
For DD, there were 160 and 196 genes with FDR ≤ 0.05
and 0.1, respectively. Only 52 of 160 genes with FDR ≤
0.05 were among the 93 genome-wide significant genes
reported by a recent DD study [70] (see below); 98 genes
are novel. The 98 genes also included QRICH1 (FDR =
3.15 ×10−5), which was reported as a suggestive DD gene
[70]. Like ID, the total MiD+LoF DN counts of these 98
genes were not high (between 2 and 6). Surprisingly, 54 of
the 98 novel genes were strongly supported in our results
(FDR < 0.01). We assessed the known DD genes in the
93 genes with FDR > 0.05 and saw two common reasons
for the differences. Note that we did not analyze the 17
known DD genes on the X chromosome. Most often, our
MiD counts were lower than the missense counts of the
previous study, since we defined MiD mutations by the
intersection of seven prediction algorithms. In addition,
extTADA used only the data from 4,293 trios while [70]
was a meta-analysis with data from other smaller studies.
Still, our results are in agreement with previously pub-
lished DD gene results (62 of 75 known DD genes on
non-chromosome X have extTADA FDR≤ 0.1; extTADA
FDR vs published P, Spearman’s ρ = 0.78, P = 2×10−16).
We sought to validate the large number of novel signifi-
cant DD genes compared with those of [70] using the same
data. First, we compared the enrichment of our candidate
gene sets for known DD genes and our novel DD genes.
We found that many of the same gene sets were signifi-
cantly enriched in both previously known and our novel
DD genes, with very strong concordance across gene sets
(Additional file 1: Figure S14). Altogether, 92 of 98 novel
DD genes had pLI and RVIS information. The median
pLI was 0.997 (observed 0.997; μ = 0.033, σ = 0.036,
z = 26.46, empirical p < 9.99 × 10−5). The median
of the RVISs was −0.92 (observed −0.92, simulated data:
μ = −0.02, σ = 0.07, z = −11.86, empirical p was
< 9.99 × 10−5). We also found that 43 of the 98 novel
DD genes occur in the latest list of curated DD genes
(described above), showing that extTADA was able to
detect DD genes later identified in other studies. Alto-
gether, 50 of the 55 novel genes not in the curated DD
gene list of had pLI/RVIS information. The median of
the 50 pLI values was 0.9415 (observed 0.94, simulated
data: μ = 0.045, σ = 0.064, z = 13.95, empirical p
was <9.99 × 10−5). The median of the RVISs was −0.72
(observed −0.72, simulated data: μ = −0.01, σ = 0.10,
z = −6.87, empirical p < 9.99 × 10−5). Finally, we used
GeNets with the InWeb protein–protein interaction (PPI)
network [64] to test the connections between the 98 novel
and 93 known genes (191 genes in total). Out of 191 genes,
94 (46 known and 48 novel) were connected to eight com-
munities (overall p = 0.006, and community connectivity
p < 2 × 10−3) (Fig. 4).
Power analysis under inferred genetic architecture
We simulated risk-gene discovery using extTADA for the
genetic architecture of SCZ inferred from the current data
(Fig. 5 and Additional file 1: Figure S15), using the CC
population sample with highest mean RR. Samples sizes
from 500 to 20,000 trio families and from 1,000 to 50,000
cases (number of controls = number of cases) were simu-
lated as in our validation analyses, using parameters from
the posterior distribution samples given the SCZ data. The
number of risk genes with FDR ≤ 0.05 ranged from 0 to
238. Based on this analysis, we expect >50 risk genes for
total sample sizes of trio families plus CC pairs of∼20,000.
The results suggest that, assuming sequencing costs are
proportional to the number of individuals, generating CC
data is more efficient than generating trio data despite the
larger relative risk of DN mutations.
Gene-set enrichment
Known and novel gene sets are enriched in SCZ
risk genes from extTADA We tested 185 gene sets
previously implicated in SCZ genetics or with strong
evidence for relevance to SCZ rare variation [5, 7, 15,
39, 42, 68] (Additional file 1: Table S2). FDR-significant
results (adjusted p < 0.05) were observed for 17 gene
sets including those previously reported using these
data [5–7] (Table 2). The most significant gene sets
were missense constrained and LoF intolerant (pLI09)
genes, targets of RBFOX1/3 and RBFOX2 splicing fac-
tors, CHD8 promoter targets, targets of the fragile X
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Fig. 4 GeNets network analysis for developmental disorder significant genes (p < 2 × 10−3). These are 93 genome-wide significant genes from [70]
and 98 significant genes (FDR < 0.05 from extTADA) not in the 93 genes. Triangular shapes are the 98 novel genes from extTADA. FDR false
discovery rate
mental retardation protein (FMRP), and CELF4 tar-
gets (all p < 2.0 × 10−4, adjusted p ≤ 7.13 × 10−3,
Table 2). Genes harboring DN single-nucleotide poly-
morphisms (SNPs) and indels in DD, and post-synaptic
density activity-regulated cytoskeleton-associated (ARC),
NMDA-receptor (NMDAR), and mGluR5 complexes
were also enriched. Genes exhibiting an allelic bias
in neuronal RNA-seq data [39] were also enriched
in SCZ extTADA results (p = 1.9 × 10−3, adjusted
p = 2.58 × 10−2). The two brain RNA-seq co-expression
modules derived from the hippocampus [47], M3 and
M13, were also significant. Finally, significant enrich-
ment was also obtained for the mouse mutant gene
sets with psychiatric-relevant phenotypes includ-
ing abnormal emotion or affect behavior, abnormal
cued conditioning behavior, and abnormal sensory
capabilities/reflexes/nociception (FDR < 0.05).
To test more novel gene sets for enrichment in the
SCZ extTADA results, we added gene sets from GO,
KEGG, REACTOME, C3 from MSigDB [72], and The
Mouse Genome Database, filtered for sets includ-
ing 100–5,000 genes (see ‘Methods’ for details), and
FDR-adjusted for the full set of 2,269 gene sets tested
(Additional file 1: Table S20). Significant results were
observed in eight gene sets including five of the known
gene sets. The top known gene sets still had the low-
est p values in these results. We observed significant
enrichment of two C3 conserved non-coding motif
gene sets [73]: GGGAGGRR_V$MAZ_Q6, genes con-
taining the conserved M24 GGGAGGRR motif, and
ACAGGGT,MIR-10A,MIR-10B, including microRNA
MIR10A/B targets; and MP:0005179, decreased circu-
lating cholesterol level less than the normal amount
(Additional file 2: Table S20).
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Fig. 5 Number of risk genes for different sample sizes based on the genetic architecture predicted by extTADA. Case–control number is only for
cases (or controls); therefore, if case–control number = 10,000, this means cases + controls = 20,000. The numbers in brackets show risk-gene
numbers if we use only case–control data or only de novo mutation data
Multiple gene sets are enriched across NDDs
We saw above that genes containing DN mutations
in several of the diseases studied here are enriched
in SCZ extTADA results. We, therefore, tested gene
set enrichment in the four NDDs and combined this
information with the SCZ gene-set information above
(Additional file 2: Tables S21 and S22). Of the 185 known
or strong-candidate gene sets tested in SCZ, 106, 116,
68, and 60 gene sets were significant (FDR < 0.05)
for ID, DD, ASD, and EPI, respectively. There were 11
gene sets that were significant across all five diseases:
constrained, PLI09, rbfox2/13, FMRP targets, CELF4,
ARC, NMDAR network, abnormal emotion/affect behav-
ior, abnormal sensory capabilities/reflexes/nociception,
abnormal excitatory postsynaptic currents, and hip-
pocampus co-expression module M3 [47]. The significant
result of genes in M3 replicated the result of [47]. How-
ever, we note that many more gene sets were significant
across two or more NDDs, but not SCZ (Fig. 6). Our
broader set of 2,269 gene sets showed a similar pattern of
sharing; there were only four gene sets that were signif-
icant (FDR-adjusted p < 0.05) in all five diseases, while
many more gene sets were significant across two or more
NDDs (Fig. 6).
To validate the gene-set results above, we tested gene-
set enrichment using the number of genes in the gene set
that were in the extTADA top 500 genes. We saw high
correlations between the PP-mean-based approach above
and this approach (Additional file 1: Figure S16).
Network facilitated interpretation of NDD risk genes
Overlap among NDD extTADA results There was no
gene significant across SCZ and the four NDDs with FDR
< 0.05 or 0.1. Only SCN2A was significant across the
four NDDs with these thresholds, but was not in SCZ
(FDR = 0.35). This gene has been reported as a strong
risk gene for multiple NDDs (reviewed in [2]). Only one
additional gene, STXBP1, was significant across the four
NDDs when the threshold FDR was increased to 0.3 and
it was not significant for SCZ (FDR = 0.9). At FDR <
0.3, several genes were shared among two or three NDDs,
whereas only three genes were shared between SCZ and
any NDD (Fig. 6). We also calculated the correlations
between risk-gene PPs for all diseases. Interestingly, high
correlations were observed for the four NDDs (ρ > 0.5)
but not for SCZ and the NDDs (ρ < 0.3, Fig. 6), either
for all genes or for significant/suggestive genes in any
disease. The pattern of sharing of top extTADA results
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Table 2 Enrichment of known gene sets from extTADA results for schizophrenia
Gene set Gene number Overlapping gene number p value FDR
Constrained 1003 939 3.3e-06 6.2e-04
pLI09 3488 3241 1.0e-05 8.2e-04
rbfox2 3068 2895 1.3e-05 8.2e-04
chd8.human_brain 2798 2601 5.0e-05 2.3e-03
rbfox13 3445 3230 1.7e-04 6.3e-03
FMRP_targets 839 792 2.1e-04 6.5e-03
celf4 2675 2468 2.7e-04 7.1e-03
Module.M3 162 145 5.6e-04 1.3e-02
DD.allDenovoMiDandLoF 1271 1271 7.0e-04 1.4e-02
ARC 28 25 1.0e-03 1.8e-02
NMDAR_network 61 58 1.5e-03 2.3e-02
abnormal_emotionORaffect_behavior 392 363 1.5e-03 2.3e-02
AlleleBiasedExpression.Neuron 802 619 1.9e-03 2.6e-02
Module.M13 149 129 2.0e-03 2.6e-02
abnormal_cued_conditioning_behavior 74 67 2.5e-03 2.9e-02
mGluR5 39 36 2.4e-03 2.9e-02
abnormal_sensory_capabilitiesORreflexesORnociception 607 579 4.5e-03 4.9e-02
mir137 3260 2940 7.0e-03 6.5e-02
abnormal_behavior 2037 1937 7.0e-03 6.5e-02
Pardinas2017_extTable9 534 522 7.0e-03 6.5e-02
PSD-95_(core) 65 57 8.0e-03 6.7e-02
abnormal_excitatory_postsynaptic_currents 73 67 8.0e-03 6.7e-02
list.EPI.43genes.2017.Epi4K.2017 43 38 9.2e-03 7.2e-02
abnormal_socialORconspecific_interaction 257 238 9.4e-03 7.2e-02
abnormal_associative_learning 204 190 1.5e-02 1.1e-01
abnormal_social_investigation 64 54 1.8e-02 1.2e-01
Module.M1 1244 1071 1.8e-02 1.2e-01
synaptome 1887 1816 1.9e-02 1.3e-01
abnormal_motor_capabilitiesORcoordinationORmovement 1398 1326 2.0e-02 1.3e-01
CYFIP1_all 37 34 2.1e-02 1.3e-01
abnormal_fearORanxiety-related_behavior 232 213 2.3e-02 1.4e-01
abnormal_behavioral_response_to_xenobiotic 219 208 3.0e-02 1.7e-01
abnormal_learningORmemoryORconditioning 449 414 3.1e-02 1.7e-01
abnormal_brain_size 193 180 3.6e-02 1.8e-01
abnormal_contextual_conditioning_behavior 95 88 3.4e-02 1.8e-01
abnormal_excitatory_postsynaptic_potential 64 58 3.5e-02 1.8e-01
abnormal_aggression-related_behavior 69 62 3.7e-02 1.8e-01
Module.M2 38 35 4.1e-02 2.0e-01
abnormal_discrimination_learning 21 20 4.3e-02 2.0e-01
These p values were obtained from 10,000,000 simulations, and then adjusted using the method of [58]. The information for these gene sets is summarized in Additional
file 1: Table S2. The second column (Gene number) shows the number of genes in the gene set. The third column shows the number of overlapping genes between the
gene sets and the 19,358 genes used by extTADA.
FDR false discovery rate
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Fig. 6 Comparing between five conditions. Top left: Overlaps of top significant genes (FDR < 0.3). Top right: Correlations of posterior probabilities
(PPs) between SCZ, ASD, DD, ID, and EPI (all p values <0.0001). These results are calculated using PPs from extTADA. Bottom: Overlaps of
significant gene sets in SCZ, ASD, EPI, DD, and ID. These results are for 185 and 1,879 gene sets, respectively. ASD autism spectrum disorders, DD
developmental disorder, EPI epilepsy, FDR false discovery rate, ID intellectual disability, PP posterior probability, SCZ schizophrenia
across diseases was consistent when examining gene set
enrichment (Fig. 6).
Given the high level of sharing among neurodevelop-
mental disease risk genes and the large number of novel
significant genes we identified, we undertook network
analyses to assess and interpret the neurodevelopmental
disease risk genes. We chose 288 NDD genes with differ-
ent FDR thresholds to balance the number of significant
genes across the four NDDs. These thresholds were 0.05
for DD, 0.1 for ASD and ID, and 0.5 for EPI.
First, we used GeNets [64] to test for significant con-
nectedness and structure of NDD genes in the InWeb
PPI network. Including second-degree indirect connec-
tions, the 288 NDD genes were connected with 89 can-
didate genes to make a network of 377 genes. These
377 genes were connected in seven communities (sub-
networks, C1–C7), including 149 of the 288 NDD genes
(overall connectivity p value and connectivity p values for
each community <1.3× 10−5, Fig. 7 and Additional file 2:
Table S23). Canonical pathway enrichment was observed
for five communities, suggesting that they are function-
ally distinct. Significant pathways included beta-catenin
nuclear signaling, transcriptional regulation of white
adipocyte differentiation, WNT signaling pathway, and
circadian clock (C2); release of several neurotransmitters
(C3); spliceosome (C4); ribosome and 3′ UTR-mediated
translational regulation (C5); and neurotransmitter recep-
tor binding and downstream transmission in the postsy-
naptic cell, calcium signaling, and post NMDA receptor
activation events (C6) (Additional file 2: Table S24). Sim-
ilar results were obtained on restricting the network to
direct edges only (connectivity p < 0.002, Additional
file 1: Figure S17), although the resulting 12 communities
were less functionally distinct in pathway enrichment.
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Fig. 7 Analyzing results for 288 neurodevelopmental disorder genes. a GeNets results for the top 288 neurodevelopmental disorder genes. Here,
149/288 genes were connected into seven main communities (colored genes) and the unconnected genes were put into the eighth community. b
Enrichment of the 288 genes in different cell types. c Grouping the 288 genes to distinct spatiotemporal expression. Genes were clustered into eight
groups using a hierarchical clustering method (color bar). d The proportions of different clusters in the eight communities
Second, we used mouse single-cell RNA-seq data [54]
to test NDD gene enrichment across brain cell types.
Significant results were observed for hippocampal CA1
pyramidal cells (p = 1.6 × 10−9), followed by neurob-
lasts, medium spiny neuron cells, somatosensory pyrami-
dal cells, and dopaminergic neuroblasts (p < 6.6 × 10−4,
Fig. 7). We further tested each GeNets PPI community
separately (Additional file 1: Figure S18), and found
multiple cell types enriched in five communities, C2–
C6, consistent with their regulatory or synaptic pathway
enrichment. Specifically, C2, C4, and C5 were significantly
enriched in neuroblasts and neural progenitor cells while
C3 and C6 were enriched for pyramidal CA1 and SS cells
(among a few others).
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Third, we used BRAINSPAN RNA-seq data to cluster
the 288 genes based on their spatiotemporal expression
in the developing brain (Fig. 7). The genes clustered into
eight groups, and again correlated with PPI communities.
Genes in prenatally expressed groups (clusters 1, 3, and 4)
were overrepresented in regulatory communities C2 and
C4 (p = 3.78 × 10−5). Postnatally expressed groups (clus-
ters 5, 7, and 8) were in higher proportions in the synaptic
communities C3 and C6 (p = 1.42 × 10−7).
Discussion
In this work, we built a pipeline, extTADA, for the inte-
grated Bayesian analysis of DN mutations and rare CC
variants to infer rare-variant genetic architecture parame-
ters and identify risk genes. We applied extTADA to data
available for SCZ and four other NDDs (Additional file 1:
Figure S1).
The extTADA pipeline
extTADA is based on previous work in autism sequencing
studies, TADA [16, 31]. It conducts a full Bayesian analy-
sis of a simple rare-variant genetic architecture model and
it borrows information across all annotation categories
and DN and CC samples in genetic parameter infer-
ence, which is critical for sparse rare-variant sequence
data. Using MCMC, extTADA samples from the joint
posterior density of risk-gene proportion and mean rel-
ative risk parameters, and provides gene-level disease-
association BFs, PPs, and FDRs. We hope that extTADA
(https://github.com/hoangtn/extTADA) will be generally
useful for rare-variant analyses across complex traits.
extTADA can be used for rare CC variant and/or DN
mutation data. The current TADA version uses multiple
steps or requires prior information for genetic parameters
[8, 74, 75], whileextTADA jointly estimates all parameters
in a single step without requiring any prior information. If
multiple variant categories are used and at least one has a
high mean RR, then the parameter results can be accurate
for a range of sample sizes (Additional file 1: Figures S6
and S7).
The inference of rare-variant genetic architecture is of
great interest in its own right [76], but of course risk-gene
discovery is a primary objective of statistical genetics.
We have shown how the two are not separable through
a power analysis of larger sample numbers under the
inferred genetic architecture parameters (Fig. 5). These
analyses, incorporated into extTADA, show how study
design should be influenced by an analysis of currently
available data.
As in all Bayesian and likelihood analyses, wemust spec-
ify a statistical model; the true model underlying the data
is unknown and could in principle yield different results.
This is addressed by analyzing a simple model that can
allow illustrative, interpretable results, and by assessing
sensitivity to alternative model specifications. extTADA
uses relatively agnostic hyper-parameter prior distribu-
tions (Additional file 1: Figure S2), without previously
known risk-gene seeds. extTADA assumes that differ-
ent variant classes share risk genes such that the mixture
model parameter π applies to all data types, facilitating
borrowing of information across classes. This is supported
by convergent DN and CC rare-variant results in SCZ
[5–8] (Additional file 1: Table S9); however, some evi-
dence exists for disjoint risk genes for DN vs CC protein-
truncating variants e.g., in congenital heart disease [77].
We assume Poisson-distributed counts data and Gamma-
distributed mean RR across genes for analytical conve-
nience. The Poisson distribution is likely to approximate
genetic counts data well [16], assuming linkage disequi-
librium can be ignored and that stratification has been
adequately addressed. Poisson DN counts further assume
known mutation rates; in our data, mutation rate adjust-
ment for silent DN rates was actually anti-conservative
(except for DD). Differences between DN studies are not
unlikely even though previous studies of [8, 31] did not
adjust mutation rates to account for it. Additional lim-
itations include that we are using public data sets from
different sequencing centers, with different technologies
and coverages. Thus, although we developed extTADA to
utilize summary counts data, care must be taken to avoid
sample heterogeneity, particularly when individual-level
data are not available. The ability to incorporate covari-
ates, perhaps by modeling Gaussian sample frequency
data, would be an important further extension of TADA-
like models. In this study, BFs and FDRs are used to obtain
the statistical significance of a gene. These measurements
can be converted to p values using a simulation-based
method implemented in the TADA package. A detailed
explanation of this approach was presented in [16].
Insights for SCZ
The current study generally replicated previous studies
and generated new insights for SCZ. In this study, we
described in detail the rare-variant genetic architecture of
SCZ. It appears more complex than those of ASD, ID, DD,
and EPI; the estimated number of SCZ risk genes, ∼1,551,
is higher than those of the four other NDDs, and their
RR is weaker (Figs. 2 and 3, Table 1). Based on our infer-
ence, we showed that tens of thousands of samples are
required to identify many rare-variant risk genes (≥50)
[76], and that, in contrast to autism studies [16, 31],
CC studies may be more efficient than trio stud-
ies in risk-gene identification. We found that SETD1A
[8, 25] is the most significant gene across analyses (FDR ∼
1.5× 10−3), and that TAF13 [6] is FDR significant. Of two
genes with 0.05 < FDR < 0.1, rare duplications covering
RB1CC1 have been reported in SCZ [78] and in ID and/or
DD [79]. Two novel conserved non-coding motif gene
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sets showing brain-specific expression [73] were enriched
(Additional file 1: Table S20), including targets of the
transcription factor MAZ and of microRNAs MIR10A/B.
In addition, we see a slight overlap between rare and
common variant genes [15] (p = 0.007, FDR = 0.06).
Insights for NDDs
We used extTADA to infer genetic parameters for four
other NDDs: ASD, EPI, DD, and ID (Table 1, Fig. 3). The
ASD results from extTADA are comparable to previous
results [16, 31]. We found lower risk-gene proportions
particularly for DD and ID, and exceptionally high DN
MiD mean RR estimated for EPI (also consistent with
previous analyses [80]). The small estimated π and large
RR ( ˆ¯γ ) facilitated the identification of novel risk genes,
particularly for DD. We did not restrict our primary anal-
yses to private DN mutations (not in ExAC) as recently
discussed [81]; however, we note that mutation rate cali-
bration might be required for analyses focusing on private
mutations. Nonetheless, multiple ID/DD genes discov-
ered in this study are in lists of curated ID/DD genes. In
addition, our novel significant genes have similarly high
conservation (e.g., pLI and RVIS), like recently discovered
ID/DD genes [41]. This shows that using both private and
non-private DN mutations provide power for finding sig-
nificant genes. One might expect that the large estimated
proportions of risk genes (π ) might correspond to large
mutational targets for disease risk and substantial com-
mon SNP heritability estimates, as observed for ASD and
SCZ [82, 83]; however, the large reported SNP-heritability
for EPI [84] seems an exception to this pattern, and data
for more disorders may better inform this hypothesis. We
also highlight the sharing of risk genes across the NDDs
(Fig. 6). Multi-phenotype analyses leveraging this sharing
could have higher power for detecting novel risk genes.
We conducted network analyses of 288 top NDD risk
genes from extTADA. We identified highly significant
PPI connectivity and communities differentially enriched
for functionally distinct canonical pathways (Fig. 7 and
Additional file 2: Table S24). A substantial number of
the genes found are synaptic, and particularly present in
communities C3 (presynaptic) and C6 (postsynaptic).
The presynaptic PPI community identified in this study
(C3, Fig. 7) accumulates genes for which synaptic pheno-
types are particularly strong in null mutantmice (STXBP1,
STX1B, SYT1, RIMS1, and VAMP2). STXBP1, the only
significant gene across the four NDDs (FDR < 0.3),
is involved in preparing synaptic vesicles for regulated
secretion (reviewed in [85]). The stxbp1 (munc18-1) null
mutant shows a loss of all aspects of synaptic transmission
[86] and it is the strongest phenotype among all mutants
described to date for presynaptic genes. The loss of one
copy of the gene in mice leads to subtle synaptic defects
[87], which are more severe in inhibitory neurons than
in excitatory neurons [87]. Therefore, this implicates an
excitation/inhibition imbalance, a central aspect in EPI
pathogenesis, which is implicated also in autism and SCZ
[88]. Known clinical features of DN heterozygous STXBP
mutations (reviewed in [89]) include severe ID, seizures,
and autistic traits [89].
Of the postsynaptic density proteins, C6 includes
the prerequisite glutamate-gated ion channel-forming
subunit GRIN1 of the NMDA receptor complex. In
contrast to AMPA-type glutamate receptor subunits,
which are not present, NMDARs are important for
Ca-dependent signaling and plasticity processes. The Ca-
dependent calmodulin kinase II (CAMK2A) and phos-
phatase PPP3CA are also identified as NDD risk genes in
C6. Interestingly, PPP3CA has just been recently identi-
fied as a novel epileptic encephalopathy gene [90]. Other
important protein phosphatases are found in different
communities: PPP1CB in C5 and PPP2R5D in C2. Muta-
tions in these Ca-mediated signaling proteins are well
known to affect synaptic plasticity and lead to major
neuronal dysfunction [91–95].
The postsynaptic community C6 also contains the
three GABA-binding beta subunits (GABRB1-3) of the
GABAA receptor (out of the myriad of GABAA receptor
subunit diversity), G-protein coupled receptor signaling
(GABBR2, RGS14, and GNAO1), cell adherence-mediated
signaling (CNNTD1 and CNNTB1 in C2), and the major
postsynaptic density protein-interaction scaffold organiz-
ing proteins DLG4, SHANK3, and SYNGAP1, mutants
of which have been shown to have a major impact on
synaptic function [96, 97]. Also notable among the 288
NDD risk genes are ion channels with roles in excitability
including calcium channel subunits CACNA1A/1E (C6);
the auxiliary calcium channel subunit CACNA2D3 (C8);
three pore-forming sodium channel subunits, SCN8A
(C6), SCN1A (C5), and the well-known strong NDD
risk gene SCN2A (C8); and potassium channel sub-
units KCNQ2/3 (C8) [98]. Finally, transcriptional activa-
tor AUTS2 occurs in unconnected C8 and is a candidate
for NDDs including ASD, ID, and DD [99].
In single-cell RNA-seq data, the top enriched cell types
were CA1 pyramidal cells and striatal medium spiny
cells, similar to SCZ [54]. In contrast to SCZ, neu-
roblasts and neural progenitor cells were also clearly
enriched for NDDs. Enrichment in neuroblasts and
neural progenitor cells was driven by PPI communi-
ties (C2, C4, and C5) enriched in regulatory path-
ways, while enrichment in neurons was driven by the
synaptic communities (C3 and C6) (Additional file 1:
Figure S18). Expression of NDD genes across develop-
ment correlated with PPI communities and scRNA-seq
enrichment. The majority of the 288 NDD genes are
expressed in the brain prenatally [100–102], particu-
larly genes in regulatory PPI communities [103, 104].
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Multiple NDD genes are also expressed across devel-
opment stages [105], including those in synaptic com-
munities. These analyses reveal that different cellular
machinery is involved in NDD etiology, and together
with the occurrence of at least some known interactors
across PPI communities (see above), this suggests that
even synaptic proteins confer risk in pre- and postnatal
stages of development, perhaps through as yet unknown
mechanisms.
Limitations of the current study
There are limitations of the current study. First, there are
inherent limitations to model-based analyses, as noted
above. Second, we used limited variant annotation cate-
gories based on our previous studies [7, 16, 25]; we did
not use all non-synonymous DN mutations [6, 70], con-
tributing to the differences between our significant DD
genes and previously published results [70], and did not
ExAC-filter DN mutations [81]. As with any genetic anal-
ysis, our findings should be replicated and validated in
future studies. Finally, the current sample sizes are not
large: only approximately 1,000 trios for SCZ and ID, and
only 356 for EPI, resulting in broad CIs. The EPI parame-
ters in particular did not show strong convergence (which
may increase sensitivity to prior distributions). Future
studies with more comprehensive sets of variant cate-
gories and larger sample sizes are likely to improve the
current findings.
Conclusions
We have developed the extTADA pipeline and analyzed
rare variants in SCZ and four NDDs. For SCZ, we gen-
erated new insights particularly for rare-variant genetic
architecture. It is more complex than the four other NDDs
with a larger risk-gene proportion. For developmental
delay (DD), 98 new significant genes were identified and
validated in silico. These genes are highly connected with
previous DD genes in a PPI network, and have similar con-
servation and gene set enrichment to known DD genes.
To understand NDD genes better, we further analyzed
288 top NDD genes from extTADA. PPI network analysis
shows that these genes are strongly connected in func-
tionally distinct subnetworks based on canonical pathway
enrichment, single-cell RNA-seq cell types, and develop-
mental transcriptomic data, revealing some of the most
important players and processes dysregulated in NDDs.
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